Home | Welcome to Contract Pharma   
Last Updated Saturday, May 25 2013
Print RSS Feed

Breaking News

Related Searches: Trials & Filings

May 24, 2007
Exelixis has submitted an IND application to the FDA for XL019. In preclinical studies, the compound has shown to be a potent, selective and orally available small molecule inhibitor of the cytoplasmic tyrosine kinase JAK2, according to the company.…  Read More »

May 24, 2007
Nektar Therapeutics has announced plans to restructure, reducing its annual spending by $65 million. As part of this initiative, the company will fire 200 full-time workers, comprising nearly one-quarter of its workforce. In its press announcement, r…  Read More »

May 23, 2007
Draxis Pharma, the CMO division of Draxis Health Inc., recently received word from the FDA that its Montreal facilities passed inspection. FDA conducted inspections of all six production and quality systems at Draxis Pharma in January 2007. The inspe…  Read More »

May 22, 2007
Albany Molecular Research, Inc. (AMRI) has signed anagreement to acquire two pharmaceutical manufacturing sites, along with additional land for future expansion, in Aurangabad and Navi Mumbai, India. AMRI will acquire the assets -- including faciliti…  Read More »

May 22, 2007
Quintiles Transnational Corp. and Thermo Fisher Scientific has established Cenduit, a joint venture to provide Interactive Response Technology (IRT) services for pharmaceutical and biotechnology product development. IRT is a technology platform that…  Read More »

May 22, 2007
Several Contract Research Organizations have formed a CRO Service Alliance (CROSA) in Shanghai's Zhangjiang HiTech Park. According to a press report, this is a first for China and is intended to take advantage of "specialized expertise from the…  Read More »

May 21, 2007
Morphotek, Inc., a U.S. subsidiary of Eisai has entered into agreement with CMC Biopharmaceuticals of Copenhagen, Denmark for development, GMP manufacturing and regulatory documentation support of MORAb-028, a therapeutic antibody targeting advanced…  Read More »

May 21, 2007
Eden Biodesign Ltd. has been licensed by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to manufacture Investigational Medicinal Products (IMPs) at its new facility in Liverpool, UK. The UK National Biomanufacturing Centre came on-…  Read More »

May 21, 2007
Pfizer Global R&D president Dr. John LaMattina will retire from Pfizer by the end of this year, after 30 years with the company. Pfizer has begun a search both inside and outside the company for his successor, and Dr. LaMattina will remain during…  Read More »

May 18, 2007
William J. Sharbaugh has been named chief operating officer, PPD, effective May 31. Mr. Sharbaugh joins the company from Bristol-Myers Squibb, where he most recently served as vice president, global development operations, responsible for strategic d…  Read More »

May 18, 2007
AstraZeneca received approval from the FDA for Seroquel XR Extended-Release Tablets, a once-daily medicine for the treatment of schizophrenia in adult patients. The Seroquel XR development program was based on the need for a wider choice of medicines…  Read More »

May 18, 2007
Patricia A. Steigerwald, MS, RN has been promoted to vice president, Global Late Phase, Kendle. In this role she will provide executive leadership to drive continued growth of the company's Late Phase brand globally, with a focus on the design and co…  Read More »

May 17, 2007
AAIPharma, Inc. completed the acquisition of Instituto de Pesquisa Clinica de Sao Paulo, Ltd. (IPCSP), a CRO in Brazil. The acquisition of IPCSP adds to the company's existing operations in South America, in Argentina and Peru. "Expanding A…  Read More »

May 17, 2007
Millennium Pharmaceuticals has initiated patient dosing in a clinical program designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MLN0002 derived from a newly engineered, commercially scaleable cell line. MLN0002 i…  Read More »

May 17, 2007
Braham Shroot, Ph.D. has been appointed chief scientific officer of Barrier Therapeutics. In this role, he will manage the company's R&D activities, reporting to Geert Cauwenbergh, Ph.D., chief executive officer. "Dr. Shroot's extensive…  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On